Drugs / Activated T Cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05341947 | Jun 2026 → Dec 2027 | glioblastoma | Jeremy Rudnick, M.D | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT00837135 | Jan 2008 → Oct 2009 | malignant pancreatic neoplasm | University of Pennsylvania | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Activated T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05341947 ↗ |
| Known as | ATC | “Activated T cells (ATC) administered intravenously at one timepoint” NCT05341947 ↗ |
| Modality | Cell therapy | “adoptive T-cell transfer” NCT00837135 ↗ |
| Route | Intravenous | “administered intravenously” NCT05341947 ↗ |